Pfizer Pill’s Phase 3 Data in Vitiligo Pave Way for FDA, EMA Submissions
Pfizer’s Litfulo significantly improved skin pigment measures in two pivotal studies in vitiligo, results that…
Pfizer Pill’s Phase 3 Data in Vitiligo Pave Way for FDA, EMA Submissions
Pfizer’s Litfulo significantly improved skin pigment measures in two pivotal studies in vitiligo, results that were presented during European Academy of Dermatology and Venereology annual meeting. If Pfizer’s daily pill is approved, it would compete against an Incyte topical cream that is currently the only FDA-approved therapy for this autoimmune skin disorder. The post Pfizer…
What Comes Next for AI? Lessons From San Diego
After a full day of conversations with healthcare leaders at the Healthcare Innovation San Diego Summit, one thing was clear: The conversation is shifting from what AI can do to how health systems can make it work.
It’s Time We Reframe Healthcare Organizational Culture Using Behavioral Science
Data, behavioral insights, and experimentation can be used to understand how stress, motivation, and trust shape company culture. Positively changing company culture leads to direct improvements in patient health outcomes, clinician wellbeing, and company performance. The post It’s Time We Reframe Healthcare Organizational Culture Using Behavioral Science appeared first on MedCity News.
Hospitals’ Cost Containment Conundrum
[Sponsored] In this webinar pharmacy leaders share how hospitals are using stewardship as a sustainability strategy to control costs and ease the load on pharmacists. The post Hospitals’ Cost Containment Conundrum appeared first on MedCity News.
Midterms Have Revived Universal Healthcare Debate. These States Are Ahead of Everyone.
Democratic congressional members and candidates are already planning to use any midterm election gains to expand health coverage, including boosting Affordable Care Act subsidies, reversing Medicaid cuts, and lowering the Medicare eligibility age. But Democratic strongholds across the country — including Oregon, California, New York, and Washington — have more ambitious goals: single-payer, universal healthcare…
Patient Dies by Suicide After ‘Insurance Issue’ Delayed Medicine for Lung Disease Flare-Ups
If you or someone you know may be experiencing a mental health crisis, contact the 988 Suicide & Crisis Lifeline by dialing or texting “988.” KYLE, Texas — Kenney Blewett was diagnosed with lung disease more than a decade ago but started experiencing flare-ups this year that made him feel like he couldn’t breathe. Blewett…
You Say “AI,” I Hear “Organoid”
By KIM BELLARD I must admit, ever since I learned about, and wrote about (OI May Be the New AI), “organoid intelligence” over three years ago, I’ve been looking to do a follow-up. I mean, sure, AI is in a very exciting stage, but that stage no longer seems like the future; it seems more…
Many Medicare Part D Stand-Alone Drug Plan Enrollees Will See Modest Premium Increases for 2027, But Others Could Pay Much More If They Don’t Switch Plans
This brief analyzes the Medicare Part D stand-alone prescription drug plan (PDP) market for 2027. The analysis shows that there will be a modest reduction in the number of PDPs for 2027, along with modest premium increases less than $10 per month for many enrollees, but much larger monthly premium increases of $50 or more…
AMA: PBM Market Concentration Is On the Rise
The AMA found that OptumRx, Express Scripts, CVS Caremark and Prime Therapeutics controlled 75% of the national PBM market in 2024. The post AMA: PBM Market Concentration Is On the Rise appeared first on MedCity News.
Sanofi Puts Up $1B to Expand Regeneron Alliance and Develop Next-Gen Dupixent
Sanofi and Regeneron Pharmaceuticals will collaborate on four next-generation antibody drugs that could offer advantages over Dupixent, the blockbuster immunology drug spawned by their R&D alliance. The companies project these drugs will start reaching pivotal testing in 2029 — important because Dupixent faces patent expiration in 2031. The post Sanofi Puts Up $1B to Expand…
